Park Sung Hyun, Son Taeil, Seo Won Jun, Lee Joong Ho, Choi Youn Young, Kim Hyoung-Il, Cheong Jae-Ho, Noh Sung Hoon, Hyung Woo Jin
Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Gastric Cancer Center, Yonsei Cancer Center, Seoul, Korea.
J Gastric Cancer. 2019 Jun;19(2):212-224. doi: 10.5230/jgc.2019.19.e20. Epub 2019 Jun 7.
Splenic hilar lymph node dissection (LND) during total gastrectomy is regarded as the standard treatment for proximal advanced gastric cancer (AGC). This study aimed to investigate whether splenic hilar LND or D2 LND is essential for proximal AGC of pT2-4aN0M0 stage.
Data of curative total gastrectomies (n=370) performed from 2000 to 2010 for proximal AGC of pT2-4aN0 stage were retrospectively reviewed. Clinicopathological characteristics and long-term outcomes were compared using propensity score matching between patients who underwent splenectomy (n=43) and those who did not (n=327) and between patients who underwent D2 LND (n=122) and those who underwent D1+ LND (n=248).
Tumors of larger size and a more advanced T stage and significantly lower overall and relapse-free survival (P<0.001) were observed in the splenectomy group than in the 2 spleen-preserving groups. Before propensity score matching, worse overall and relapse-free survival (P<0.001) was observed in the splenectomy group than in the non-splenectomy group. After matching, although the overall survival became similar (P=0.123), relapse-free survival was worse in the splenectomy group (P=0.021). Compared with D1+ LND, D2 LND had no positive impact on the overall (P=0.619) and relapse-free survival (P=0.112) after propensity score matching.
Splenic hilar LND with or without splenectomy may not have an oncological benefit for patients with pathological AGC with no LN metastasis.
全胃切除术中脾门淋巴结清扫术(LND)被视为近端进展期胃癌(AGC)的标准治疗方法。本研究旨在探讨脾门LND或D2 LND对于pT2 - 4aN0M0期近端AGC是否必不可少。
回顾性分析2000年至2010年因pT2 - 4aN0期近端AGC行根治性全胃切除术(n = 370)的数据。采用倾向评分匹配法比较行脾切除术的患者(n = 43)和未行脾切除术的患者(n = 327)之间,以及行D2 LND的患者(n = 122)和行D1 + LND的患者(n = 248)之间的临床病理特征和长期预后。
与两个保脾组相比,脾切除术组观察到肿瘤体积更大、T分期更晚,总体生存率和无复发生存率显著更低(P < 0.001)。在倾向评分匹配前,脾切除术组的总体生存率和无复发生存率比非脾切除术组更差(P < 0.001)。匹配后,尽管总体生存率变得相似(P = 0.123),但脾切除术组的无复发生存率更差(P = 0.021)。倾向评分匹配后,与D1 + LND相比,D2 LND对总体生存率(P = 0.619)和无复发生存率(P = 0.112)没有积极影响。
对于无淋巴结转移的病理AGC患者,无论是否行脾切除术,脾门LND可能都没有肿瘤学益处。